Scilex Holding (SCLX) Operating Expenses (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Operating Expenses of $40.8 million for Q1 2026, up 23.95% year-over-year from $32.9 million in Q1 2025, and down 64.81% quarter-over-quarter from $115.9 million in Q4 2025.
Scilex Holding (SCLX) Operating Expenses (2020 - 2026) Analysis & Trends
Scilex Holding's Operating Expenses history runs 7 years deep, the most recent figure standing at $40.8 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 23.95% year-over-year to $40.8 million; the TTM figure through Mar 2026 stood at $384.1 million (up 169.52% YoY), while the FY2025 annual figure was $376.3 million, up 168.78% from the prior year.
- Operating Expenses for Q1 2026 stood at $40.8 million, down from $115.9 million in the prior quarter.
- The five-year high for Operating Expenses was $197.1 million in Q3 2025, with the low at $15.6 million in Q1 2022.
- The 5-year median for Operating Expenses is $32.9 million (2025), against an average of $46.9 million.
- Peak annual rise in Operating Expenses reached 11168.15% in 2022, while the deepest fall reached 52.42% in 2022.
- Scilex Holding's Operating Expenses stood at $31.7 million in 2022, then rose by 0.45% to $31.8 million in 2023, then jumped by 36.09% to $43.3 million in 2024, then soared by 167.76% to $115.9 million in 2025, then sank by 64.81% to $40.8 million in 2026.
- Business Quant data shows SCLX's Operating Expenses at $40.8 million in Q1 2026, $115.9 million in Q4 2025, and $197.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Scilex Holding | 39.35 Mn | -73.44 Mn | 3.97 Mn | 37.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.78 Mn |
| Dec 31, 2025 | 115.88 Mn |
| Sep 30, 2025 | 197.07 Mn |
| Jun 30, 2025 | 30.40 Mn |
| Mar 31, 2025 | 32.90 Mn |
| Dec 31, 2024 | 43.28 Mn |
| Sep 30, 2024 | 34.35 Mn |
| Jun 30, 2024 | 31.99 Mn |
| Mar 31, 2024 | 30.36 Mn |
| Dec 31, 2023 | 31.80 Mn |
| Sep 30, 2023 | 48.92 Mn |
| Jun 30, 2023 | 35.40 Mn |
| Mar 31, 2023 | 36.06 Mn |
| Dec 31, 2022 | 31.66 Mn |
| Sep 30, 2022 | 21.99 Mn |
| Jun 30, 2022 | 19.40 Mn |
| Mar 31, 2022 | 15.62 Mn |
| Dec 31, 2021 | 66.53 Mn |
| Sep 30, 2021 | 283,346.00 |
| Jun 30, 2021 | 172,140.00 |